NASDAQ$LYRA
Lyra Therapeutics Inc · Q1 2021 earnings
Q1 2021 earnings · · Investor relations
Briefing
Lyra Therapeutics reported financial results for the first quarter of 2021 and provided a corporate update.
Lyra Therapeutics reported a net loss of $7.8 million for the first quarter of 2021, with cash and cash equivalents totaling $66.1 million as of March 31, 2021. The company presented positive data from its LANTERN Phase 2 study of LYR-210 and appointed Robert Kern, MD, as Chief Medical Officer.
- Presented positive full data set from LANTERN Phase 2 Study of LYR-210 at COSM 2021 Virtual Event, demonstrating effectiveness in both non-polyp and polyp patients.
- Commenced first manufacturing lot at CMO to support the IND supplement and the commencement of Phase 3 clinical trial for LYR-210 around the end of the year.
- Appointed Robert Kern, MD, as Chief Medical Officer.
- Management believes Lyra has sufficient cash to fund the company through planned operations into 2023.
Headline financials
Revenue & EPS history
Lyra · Revenue · Quarterly
$25K
Revenue by segment
Lyra · $410K total across 1 segment · Q1 2023
- Collaboration revenue$410K—100.0%
Forward guidance
Lyra Therapeutics anticipates sharing results from its PK study of LYR-210 in the second quarter, along with feedback from its End-of Phase-2 meeting with the FDA around mid-year. Subject to FDA guidance, the company plans to initiate a Phase 2 trial for LYR-220 in the second half of 2021 and a Phase 3 trial of LYR-210 around the end of the year. Management believes Lyra has sufficient cash to fund the company through planned operations into 2023.
Tailwinds
- Presenting results from PK study of LYR-210 in Q2 2021.
- Sharing feedback from End-of Phase-2 meeting with the FDA around mid-year.
- Planning to initiate a Phase 2 trial for LYR-220 in the second half of 2021.
- Planning to initiate a Phase 3 trial of LYR-210 around the end of the year.
- Sufficient cash to fund operations into 2023.
Headwinds
- Uncertainty regarding FDA guidance affecting trial plans.
- Clinical trials are expensive and time-consuming
- Reliance on third parties for manufacturing and clinical trials.
- Potential adverse impacts from the COVID-19 pandemic.
- Risk of failure to obtain and maintain intellectual property rights.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2021
-1.6%
Avg return
Earnings day
-3.1%
Avg return
5 days after
-1.7%
Avg return
30 days after
29%
7 / 24 earnings
Positive
+11.0%
Q1 2024
Best reaction
-25.4%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | +0.0% | +0.1% | +52.2% | |
| Q3 2025 | -1.0% | -5.9% | -6.3% | |
| Q2 2025 | +9.5% | +8.3% | -6.8% | |
| Q1 2025 | -6.3% | -17.3% | +102.9% | |
| Q4 2024 | -4.1% | -14.8% | -39.2% | |
| Q3 2024 | -25.4% | -35.8% | -23.8% | |
| Q2 2024 | -3.3% | +4.0% | -6.6% | |
| Q1 2024 | +11.0% | -14.8% | -93.0% | |
| Q4 2023 | +2.8% | +1.0% | -14.5% | |
| Q3 2023 | +0.0% | +2.4% | +33.4% | |
| Q2 2023 | +5.4% | +13.8% | +20.8% | |
| Q1 2023 | -6.8% | -2.1% | +3.6% | |
| Q4 2022 | +6.1% | +13.8% | +22.4% | |
| Q3 2022 | -17.9% | -20.3% | -35.8% | |
| Q2 2022 | -1.7% | +0.6% | -5.2% | |
| Q1 2022 | +7.1% | +7.7% | +18.1% | |
| Q4 2021 | -4.0% | -5.8% | +22.8% | |
| Q3 2021 | -1.0% | -0.4% | -32.9% | |
| Q2 2021 | -3.9% | -0.4% | +17.6% | |
| Q1 2021 | -1.0% | -5.6% | +11.9% | |
| Q4 2020 | -4.8% | -2.2% | -20.9% | |
| Q3 2020 | +1.0% | -1.8% | -13.3% | |
| Q2 2020 | -0.9% | +0.9% | -17.8% | |
| Q1 2020 | -0.5% | +0.1% | -31.6% | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro